Clinical Trial

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in patients with unresectable hepatocellular carcinoma (HCC) and diabetes.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-22.
Trial Details
NCT Number NCT07557914
Lead Sponsor Haibo Shao
Collaborators: First Hospital of China Medical University, Liaoning Cancer Hospital & Institute, The General Hospital of Northern Theater Command, The Affiliated Hospital of Yanbian University, Harbin Medical University Third Affiliated Hospital
Conditions HCC - Hepatocellular Carcinoma, Diabetes
Enrollment 32 participants
Start Date 2026-06
Primary Completion 2029-02 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-06-03